Milademetan

N/A

Report date: 2025/12/04 20:00:08
NME

Base Information

Drug NameMilademetan
Drug Alias Namemilademetan monotosylate monohydrateDS3032bDS-3032RAIN-32
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitors
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesUterine Cervical Neoplasms +[26] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDaiichi Sankyo Uk LtdTempusRain Oncology Inc +[5] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesUterine Cervical Neoplasms +[26] 

Other Information

ATC CodeN/A
Related LinksN/A